NCT06934343Recruiting
Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer (aNSCLC). Rather than influencing regulatory decisions or clinical guidelines, the goal of this trial is to refine treatment selection among existing therapeutic options, ensuring that care is tailored to individual patient characteristics. Additionally, by generating real-world evidence, these findings will inform the design and implementation of future clinical trials. Importantly, the methodological advancements will establish a pipeline that extends beyond aNSCLC, facilitating the identification of optimal dynamic treatment regimes (DTRs) for other complex diseases.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 144400 (estimated)
- First submitted
- 28 Feb 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- University of Utah
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT06934343
What you commit to
- Study type: Observational
- Planned participants: 144400
- From 1 Sept 2024 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Fewer than one day of follow-up post-initiation of first-line (1L) therapy.
- First-line treatment limited to immunotherapy or chemoimmunotherapy (excluding other treatment regimens).
- Patients receiving second-line (2L) treatment, including those enrolled in a clinical study.
Lab values
- Presence of a targetable mutation, including ALK, BRAF, EGFR, KRAS, or ROS1.
Other
- Subjects meeting any of the following criteria at baseline will be excluded:
- PD-L1 expression \<50% at baseline (restricted to patients with PD-L1 ≥50%).
Who the study is looking for
- Subjects must meet all of the following eligibility criteria:
- Diagnosed with advanced NSCLC between January 1, 2011, and June 30, 2024.
- Follow-up available until December 31, 2024, with a minimum potential follow-up period of at least six months.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Huntsman Cancer Institute at the University of Utah Coordinator of this site? Confirm its status | Salt Lake City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.